Medical AI Provider Lunit Raises $61M in Funding Round Led By Major Global Healthcare Investors
Medical AI Provider Lunit Raises $61M in Funding Round Led By Major Global Healthcare Investors
- New investors include US life science investors HealthQuest Capital, Casdin Capital, and American Cancer Society BrightEdge, and Asia-based global healthcare investors Tybourne Capital Management and NSG Ventures
-新的投資者包括美國生命科學投資者HealthQuest Capital、Casdin Capital和美國癌症協會BrightEdge,以及總部位於亞洲的全球醫療保健投資者Tybourne Capital Management和NSG Ventures
- Following the most recent strategic investment of $26 million from Guardant Health, the company has now secured more than $135 million in total ahead of its planned KOSDAQ IPO next year
-繼Guardant Health最近2600萬美元的戰略投資之後,該公司在計劃明年進行的Kosdaq首次公開募股(IPO)之前,目前已獲得總計超過1.35億美元的資金
SEOUL, South Korea, Nov. 25, 2021 /PRNewswire/ -- Lunit, a leading medical AI provider, today announced it has raised $61 million in its Pre-IPO fundraising round ahead of the company's planned public offering on the South Korean stock market (KOSDAQ) early next year. A number of new investors have joined the round including leading US healthcare investors HealthQuest Capital, Casdin Capital, and American Cancer Society BrightEdge, as well as Asia-based global healthcare investors Tybourne Capital Management, and NSG Ventures.
韓國首爾,2021年11月25日/美通社/--領先的醫療人工智能提供商Lunit今天宣佈,在該公司計劃於明年初在韓國證券市場(Kosdaq)公開發行之前,該公司已在首次公開募股(IPO)前的一輪融資中籌集了6100萬美元。許多新的投資者已經加入了這輪融資,其中包括領先的美國醫療保健投資者HealthQuest Capital、Casdin Capital和美國癌症協會BrightEdge,以及亞洲-總部位於全球醫療保健投資者Tybourne Capital Management和NSG Ventures。
HealthQuest Capital invested $20 million of the total funding amount. HealthQuest Capital is a leading healthcare growth equity firm with funding from a number of major US healthcare systems and has extensive experience partnering with global pharmaceutical companies including Roche-Genentech, Merck, AstraZeneca, Johnson & Johnson, and Pfizer. It also has a broad network of healthcare payers such as Kaiser Permanente, Humana, and United Healthcare. Lunit is the HealthQuest Capital's first investment in Asia.
HealthQuest Capital在總籌資額中投資了2000萬美元。HealthQuest Capital是一家領先的醫療保健成長型股權公司,資金來自多個主要的美國醫療保健系統,並擁有與羅氏基因泰克、默克、阿斯利康、強生和輝瑞等全球製藥公司合作的豐富經驗。它還擁有廣泛的醫療支付者網絡,如Kaiser Permanente、Humana和United Healthcare。Lunit是HealthQuest Capital的第一筆投資亞洲.
"At HealthQuest, we're highly interested in AI advancement and its application to complex diagnostic procedures to improve accuracy and reduce complexity," said Garheng Kong, Managing Partner at HealthQuest Capital. "Lunit stands out as best-in-class for its state-of-the-art solutions (which uses a paired modality approach) across multiple products, and has significant initial commercial traction around the world. We're excited to partner with Lunit through this exciting stage of growth."
HealthQuest Capital管理合夥人江嘉恆(Gareng Kong)表示:“在HealthQuest,我們對人工智能的進步及其在複雜診斷程序中的應用非常感興趣,以提高準確性和降低複雜性。”Lunit在多種產品中以其最先進的解決方案(使用配對模式方法)脱穎而出,並在世界各地擁有重要的初步商業吸引力。我們為能與Lunit合作度過這一令人興奮的增長階段而感到興奮。“
Casdin Capital, a New York based life science focused investment firm, has invested in well over 100 biotechnology companies including Loxo Oncology, Spark Therapeutics, Foundation Medicine, and Flatiron Health, which were recent acquisition targets for major pharmaceutical companies Eli Lilly and Roche.
卡斯丁資本公司(Casdin Capital)是一家總部位於紐約的專注於生命科學的投資公司,已投資了100多家生物技術公司,包括Loxo Oncology、Spark Treeutics、Foundation Medicine和Flatiron Health,這些公司都是大型製藥公司禮來公司(Eli Lilly)和羅氏公司(Roche)最近的收購目標。
Tybourne Capital Management is a global growth investor in public and private equity markets, focusing on investments in the Healthcare, Consumer, Financials and TMT sectors. The firm was founded in 2012 and is headquartered in Hong Kong with an office in San Francisco. Tybourne manages long duration capital on behalf of prominent non-profits, university endowments, sovereigns, corporate pensions and family offices. Notable investments in healthcare include Zentalis Pharmaceuticals/Zentera Therapeutics, WuXi Biologics, Tigermed, and SK Biopharmaceuticals.
泰伯恩資本管理公司是公共和私人股本市場的全球成長型投資者,專注於醫療保健、消費、金融和TMT部門的投資。該公司成立於2012年,總部設在香港,辦事處設在舊金山。泰伯恩代表著名的非營利組織、大學捐贈基金、主權國家、企業養老金和家族理財室管理長期資本。在醫療保健領域值得注意的投資包括Zentalis製藥/Zentera治療公司、藥明生物、泰格醫藥和SK生物製藥公司。
BrightEdge is a recently established venture capital arm of American Cancer Society, and NSG Ventures is a global healthcare venture capital which Tim Lu, a serial entrepreneur and world-renowned expert in systems biology at MIT, co-founded as founding partner.
BrightEdge是美國癌症協會最近成立的風險投資機構,NSG Ventures是一家全球醫療保健風險投資公司,蒂姆·盧(Tim Lu)是一名連續創業者,也是世界知名的系統生物學專家麻省理工學院,作為創始合夥人共同創立。
The list further adds Naver, one of the leading IT companies known to be the Google of Korea, and its affiliate Naver Cloud, as well as Asia's leading venture capitals including Softbank Ventures Asia, Legend Capital, IMM Investment, Kakao Ventures, and Mirae Asset Venture Investment.
這份榜單進一步增加了被稱為韓國谷歌(Google)的領先IT公司之一Naver及其附屬公司Naver Cloud,以及亞洲的領先的風險資本包括軟銀亞洲風險投資公司、聯想資本公司、IMM投資公司、Kakao Ventures公司和未來資產風險投資公司。
"It is a great pleasure to be successfully closing this round, consisting of major biotech investors. It is a result of hard work throughout the years to establish ourselves as one of the leading medical AI companies in the world," said Brandon Suh, CEO of Lunit.
Lunit首席執行官布蘭登·蘇(Brandon Suh)表示:“很高興能成功完成這一輪由主要生物技術投資者組成的融資。這是多年來努力工作的結果,目的是將我們打造成世界領先的醫療人工智能公司之一。”
Prior to this latest round, Lunit closed a strategic investment of $26 million from Guardant Health last July. Combined with the pre-IPO round, the company has secured more than $135 million in total to date. "Our purpose of the last few investment rounds has been to find partners who would bring strategic value for our future endeavours. Through these partnerships we look forward to reinforcing our journey to conquer cancer through AI," added Suh.
在最新一輪融資之前,Lunit於去年7月完成了Guardant Health 2600萬美元的戰略投資。加上IPO前的一輪融資,到目前為止,該公司總共獲得了超過1.35億美元的資金。Suh補充道:“我們過去幾輪投資的目的是找到能夠為我們未來的努力帶來戰略價值的合作伙伴。通過這些合作伙伴關係,我們期待着加強我們通過人工智能征服癌症的旅程。”
Lunit, based in Seoul, Korea, was founded in 2013. With a mission to conquer cancer through AI, Lunit develops AI-powered diagnostic tools for cancer screening, as well as biomarkers that can accurately predict and guide which patients respond to specific cancer therapy. Its radiology solutions for chest x-ray and mammography, Lunit INSIGHT, in active partnership with various medical device giants including GE Healthcare, Philips, and FujiFilm, is commercial in 30+ countries and will also be offered in the US with its recent FDA approval.
總部位於韓國首爾的Lunit成立於2013年。Lunit的使命是通過人工智能征服癌症,該公司開發用於癌症篩查的人工智能支持的診斷工具,以及可以準確預測和指導哪些患者對特定癌症治療有反應的生物標記物。其胸部X光和乳房X光檢查放射學解決方案Lunit Insight與包括GE Healthcare、飛利浦和富士在內的多家醫療設備巨頭積極合作,已在30多個國家投入商業使用,並將在最近獲得FDA批准後在美國提供。
SOURCE Lunit
源Lunit